Bioactive porous bone graft compositions in synthetic containment

ABSTRACT

Bioactive porous bone graft implants in various forms suitable for use in bone tissue regeneration and/or repair, as well as methods of use are provided. The implants are formed of bioactive glass and have an engineered porosity. The implants may be contained in polymer for enhanced clinical results and better handling.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application relates to co-pending and co-owned U.S. patentapplication Ser. No. ______, filed Mar. 14, 2013 and entitled “BIOACTIVEPOROUS BONE GRAFT IMPLANTS”, and U.S. patent application Ser. No.______, filed Mar. 14, 2013 and entitled “BONE GRAFT IMPLANTS CONTAININGALLOGRAFT”, the contents of which are herein incorporated in theirentirety by reference.

FIELD

The present disclosure relates generally to bone graft materials andmethods of using such materials as implants for bone tissue regrowth.More particularly, the present disclosure relates to bioactive porousbone graft implants encapsulated in polymer for use in bone tissueregeneration and/or repair, as well as methods of use.

BACKGROUND

The role of bone graft materials in clinical applications to aid thehealing of bone has been well documented over the years. Most bone graftmaterials that are currently available, however, have failed to deliverthe anticipated results necessary to make these materials a routinetherapeutic application in reconstructive surgery. Improved bone graftmaterials for forming bone tissue implants that can produce reliable andconsistent results are therefore still needed and desired.

In recent years intensive studies have been made on bone graft materialsin the hopes of identifying the key features necessary to produce anideal bone graft implant, as well as to proffer a theory of themechanism of action that results in successful bone tissue growth. Atleast one recent study has suggested that a successful bone tissuescaffold should consider the physicochemical properties, morphology anddegradation kinetics of the bone being treated. (“Bone tissueengineering: from bench to bedside”, Woodruff et al., Materials Today,15(10): 430-435 (2012)). According to the study, porosity is necessaryto allow vascularization, and the desired scaffold should have a porousinterconnected pore network with surface properties that are optimizedfor cell attachment, migration, proliferation and differentiation. Atthe same time, the scaffold should be biocompatible and allow flowtransport of nutrients and metabolic waste. Just as important is thescaffold's ability to provide a controllable rate of biodegradation tocompliment cell and/or tissue growth and maturation. Finally, theability to model and/or customize the external size and shape of thescaffold is to allow a customized fit for the individual patient is ofequal importance.

Woodruff, et. al. also suggested that the rate of degradation of thescaffold must be compatible with the rate of bone tissue formation,remodeling and maturation. Recent studies have demonstrated that initialbone tissue ingrowth does not equate to tissue maturation andremodeling. According to the study, most of the currently available bonegraft implants are formulated to degrade as soon as new tissue emerges,and at a faster rate than the new bone tissue is able to mature,resulting in less than desirable clinical outcomes.

Other researchers have emphasized different aspects as the core featuresof an ideal bone graft implant. For example, many believe that theimplant's ability to provide adequate structural support or mechanicalintegrity for new cellular activity is the main factor to achievingclinical success, while others emphasize the role of porosity as the keyfeature. The roles of porosity, pore size and pore size distribution inpromoting revascularization, healing, and remodeling of bone have longbeen recognized as important contributing factors for successful bonegrafting implants. Many studies have suggested an ideal range ofporosities and pore size distributions for achieving bone graft success.However, as clinical results have shown, a biocompatible bone grafthaving the correct structure and mechanical integrity for new bonegrowth or having the requisite porosities and pore distributions alonedoes not guarantee a good clinical outcome. What is clear from thiscollective body of research is that the ideal bone graft implant shouldpossess a combination of structural and functional features that act insynergy to allow the bone graft implant to support the biologicalactivity and an effective mechanism of action as time progresses.

Currently available bone graft implants fall short of meeting theserequirements. That is, many bone graft implants tend to suffer from oneor more of the problems previously mentioned, while others may havedifferent, negatively associated complications or shortcomings. Oneexample of such a graft implant is autograft implants. Autograftimplants have acceptable physical and biological properties and exhibitthe appropriate mechanical structure and integrity for bone growth.However, the use of autogenous bone requires the patient to undergomultiple or extended surgeries, consequently increasing the time thepatient is under anesthesia, and leading to considerable pain, increasedrisk of infection and other complications, and morbidity at the donorsite.

When it comes to synthetic bone graft substitutes, the most rapidlyexpanding category consists of products based on calcium sulfate,hydroxyapatite and tricalcium phosphate. Whether in the form ofinjectable cements, blocks or morsels, these materials have a proventrack record of being effective, safe bone graft substitutes forselected clinical applications. Recently, new materials such asbioactive glass (“BAG”) have become an increasingly viable alternativeor supplement to natural bone-derived graft materials. In comparison toautograft implants, these new synthetic implants have the advantage ofavoiding painful and inherently risky harvesting procedures on patients.Also, the use of these synthetic, non-bone derived materials can reducethe risk of disease transmission. Like autograft and allograft implants,these new artificial implants can serve as osteoconductive scaffoldsthat promote bone regrowth. Preferably, the graft implant is resorbableand is eventually replaced with new bone tissue.

Many artificial bone grafts available today comprise materials that haveproperties similar to natural bone, such as implants containing calciumphosphates.

Exemplary calcium phosphate implants contain type-B carbonatedhydroxyapatite whose composition in general may be described as(Ca₅(PO₄)_(3x)(CO₃)_(x)(OH)). Calcium phosphate ceramics have beenfabricated and implanted in mammals in various forms including, but notlimited to, shaped bodies and cements. Different stoichiometricimplants, such as hydroxyapatite (HA), tricalcium phosphate (TCP),tetracalcium phosphate (TTCP), and other calcium phosphate (CaP) saltsand minerals have all been employed in attempts to match theadaptability, biocompatibility, structure, and strength of natural bone.Although calcium phosphate based materials are widely accepted, theylack the ease of handling, flexibility and capacity to serve as a liquidcarrier/storage media necessary to be used in a wide array of clinicalapplications. Calcium phosphate materials are inherently rigid, and tofacilitate handling are generally provided as part of an admixture witha carrier material; such admixtures typically have an active calciumphosphate ingredient to carrier volume ratio of about 50:50, and mayhave a ratio as low as 10:90.

As previously mentioned, the roles of porosity, pore size and pore sizedistribution in promoting revascularization, healing, and remodeling ofbone have been recognized as important contributing factors forsuccessful bone grafting. Yet currently available bone graft implantsstill lack the requisite chemical and physical properties necessary foran ideal graft implant. For instance, currently available graft implantstend to resorb too quickly (e.g., within a few weeks), while some taketoo long (e.g., over years) to resorb due to the implant's chemicalcomposition and structure. For example, certain implants made fromhydroxyapatite tend to take too long to resorb, while implants made fromcalcium sulfate or β-TCP tend to resorb too quickly. Further, if theporosity of the implant is too high (e.g., around 90%), there may not beenough base material left after resorption has taken place to supportosteoconduction. Conversely, if the porosity of the implant is too low(e.g., 10%,) then too much material must be resorbed, leading to longerresorption rates. In addition, the excess material means there may notbe enough room left in the residual graft implant for cell infiltration.Other times, the graft implants may be too soft, such that any kind ofphysical pressure exerted on them during clinical usage causes them tolose the fluids retained by them.

Accordingly, there continues to be a need for better bone graftimplants. For instance, it would be desirable to provide improved bonegraft implants offering the benefits just described, and in a form thatis even easier to handle and allows even better clinical results.Embodiments of the present disclosure address these and other needs.

SUMMARY

The present disclosure provides bone graft materials and implants formedfrom these materials that are engineered with a combination ofstructural and functional features that act in synergy to allow the bonegraft implant to support cell proliferation and new tissue growth overtime. The implants serve as cellular scaffolds to provide the necessaryporosity and pore size distribution to allow proper vascularization,optimized cell attachment, migration, proliferation, anddifferentiation. The implants are formed of synthetic materials that arebiocompatible and offer the requisite mechanical integrity to supportcontinued cell proliferation throughout the healing process. Inaddition, the materials are formulated for improved clinical handlingand allow easy modeling and/or customization of the external size andshape to produce a customized implant for the anatomic site.

In one embodiment, a porous, composite bone graft implant is provided.The implant may comprise a first component comprising a bioactive glassand a second component comprising a polymeric material. Each of thecomponents may have a different resorption capacity than the othercomponent. The composite implant may comprise a pore size distributionincluding pores characterized by pore diameters ranging from about 100nanometer to about 1 millimeter.

The first component may comprise bioactive glass fibers or bioactiveglass granules. The second component may comprise a bioabsorbablepolymer. In one embodiment, the second component is a porous coating. Inanother embodiment, the second component comprises a combination of twoor more polymers.

In one embodiment, the first component may comprise bioactive glassfibers, and the second component may comprise a coating over each of thefibers. In another embodiment, the first component may comprisebioactive glass fibers, and the second component may comprise a coatingover the plurality of fibers. In still another embodiment, the firstcomponent may comprise bioactive glass fibers, and the second componentmay comprise a woven layer surrounding the plurality of fibers.

In yet another embodiment, the first component may comprise bioactiveglass granules, and the second component may comprise a coating overeach of the granules. In even still another embodiment, the firstcomponent may comprise bioactive glass granules, and the secondcomponent may comprise a coating over the plurality of granules. In yetstill another embodiment, the first component may comprise bioactiveglass granules, and the second component may comprise a woven layersurrounding the plurality of granules.

In some embodiments, the implant may comprise a plurality of layers,wherein the volumetric ratio of first component to second componentwithin each layer is the same throughout the implant. In otherembodiments, the implant may comprise a plurality of layers, wherein thevolumetric ratio of first component to second component within one layeris different than an adjacent layer within the implant. The firstcomponent may be uniformly distributed throughout the implant, or may benon-uniformly distributed throughout the implant.

It is to be understood that both the foregoing general description andthe following detailed description are exemplary and explanatory onlyand are not restrictive of the disclosure. Additional features of thedisclosure will be set forth in part in the description which follows ormay be learned by practice of the disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated in and constitute apart of this specification, illustrate several embodiments of thedisclosure and together with the description, serve to explain theprinciples of the disclosure.

FIG. 1 illustrates a cross-sectional view of an exemplary embodiment ofan individual bioactive glass fiber having a polymeric coating of thepresent disclosure.

FIG. 2 illustrates a cross-sectional view of an exemplary embodiment ofa bone graft implant of the present disclosure in which the implantcomprises a fibrous matrix encased in a polymeric shell.

FIG. 3 illustrates a cross-sectional view of an exemplary embodiment ofa bone graft implant of the present disclosure in which the implantcomprises a fibrous matrix combined with fibrous clusters encased in apolymeric shell.

FIG. 4A illustrates a partial cutaway view of an exemplary embodiment ofa bone graft implant of the present disclosure comprising a fibrouscluster encased in a polymeric shell.

FIG. 4B illustrates a partial cutaway view of an exemplary embodiment ofa bone graft implant of the present disclosure comprising a fusedfibrous cluster encased in a polymeric shell.

FIG. 4C illustrates a partial cutaway view of an exemplary embodiment ofa bone graft implant of the present disclosure comprising a sinteredporous granule encased in a polymeric shell.

FIG. 5 illustrates a partial cutaway view of an exemplary embodiment ofa bone graft implant of the present disclosure comprising a fibrouscluster with granule encased in a polymeric shell.

FIG. 6 illustrates a partial cutaway view of an exemplary embodiment ofa bone graft implant of the present disclosure comprising a fibrouscluster with granule encased in a polymeric shell and with surfacefeatures.

FIG. 7 illustrates a partial cutaway view of an exemplary embodiment ofa bone graft implant of the present disclosure comprising a fibrouscluster within a fibrous cluster and encased in a polymeric shell.

FIG. 8: illustrates a partial cutaway view of an exemplary embodiment ofa bone graft implant of the present disclosure comprising a granularmatrix encased in a polymeric shell.

FIG. 9 illustrates a partial cutaway view of an exemplary embodiment ofa bone graft implant of the present disclosure comprising fibrousclusters within a fibrous matrix and encased in a polymeric shell.

FIG. 10A illustrates an exploded view of an exemplary embodiment of amulti-layered composite graft implant.

FIG. 10B represents the assembled multi-layered composite graft implantof FIG. 10A in a rolled form.

FIG. 11A illustrates an exploded view of an exemplary embodiment of amulti-layered composite graft implant comprising different forms ofmaterial selectively distributed throughout.

FIG. 11B represents the assembled multi-layered composite graft implantof FIG. 10A in a rolled form.

FIG. 12 illustrates a cross-sectional view of an exemplary embodiment ofa multi-layered composite graft implant comprising different forms ofmaterial uniformly distributed throughout.

FIG. 13 shows a scanning electron micrograph (SEM) of a fibrousbioactive glass implant of the present disclosure.

FIG. 14 shows a scanning electron micrograph (SEM) of a bioactive glassimplant of the present disclosure comprising a fibrous matrix withgranules.

FIG. 15 shows a scanning electron micrograph (SEM) of a fibrous clusterof the present disclosure.

FIG. 16 shows a scanning electron micrograph (SEM) of the fibrous matrixwithin the cluster of FIG. 15.

The foregoing and other features of the present disclosure will becomeapparent to one skilled in the art to which the present disclosurerelates upon consideration of the following description of exemplaryembodiments with reference to the accompanying drawings.

DETAILED DESCRIPTION OF THE EMBODIMENTS

The present disclosure provides bone graft materials and implants formedfrom these materials that are engineered with a combination ofstructural and functional features that act in synergy to allow the bonegraft implant to support cell proliferation and new tissue growth overtime. The implants provide the necessary porosity and pore sizedistribution to allow proper vascularization, optimized cell attachment,migration, proliferation, and differentiation. The implants are formedof synthetic materials that are biocompatible and offer the requisitemechanical integrity to support continued cell proliferation throughoutthe healing process. In addition, the materials are formulated forimproved handling and allow easy modeling and/or customization of theexternal size and shape of the implants to produce a customized implantfor the anatomic site.

The bone graft implants may be formed of a synthetic material that isboth biocompatible and bioabsorbable or bioresorbable. In addition, thesynthetic material may be bioactive. In one embodiment, the material maybe a material that is bioactive and forms a calcium phosphate layer onits surface upon implantation. In another embodiment, the material maycomprise a bioactive glass (“BAG”). Suitable bioactive glasses includesol gel derived bioactive glass, melt derived bioactive glass, silicabased bioactive glass, silica free bioactive glass such as borate basedbioactive glass and phosphate based bioactive glass, crystallizedbioactive glass (either partially or wholly), and bioactive glasscontaining trace elements or metals such as copper, zinc, strontium,magnesium, zinc, fluoride, mineralogical calcium sources, and the like.Examples of sol gel derived bioactive glass include S70C30 characterizedby the general implant of 70 mol % SiO₂, 30 mol % CaO. Examples of meltderived bioactive glass include 45S5 characterized by the generalimplant of 46.1 mol % SiO₂, 26.9 mol % CaO, 24.4 mol % Na₂O and 2.5 mol% P₂O₅, S53P4, and 58S characterized by the general implant of 60 mol %SiO₂, 36 mol % CaO and 4 mol % P₂O₅. Another suitable bioactive glassmay also be 13-93 bioactive glass.

The bioactive glass forms the base material from which the engineeredbone graft implants of the present disclosure are composed. Thebioactive glass may take the form of fibers, granules, or a combinationof both. By the term granules, what is meant is at least one fragment ormore of material having a non-rod shaped form, such as a rounded,spherical, globular, or irregular body.

The bioactive glass may be provided in a materially pure form.Additionally, the bioactive glass may be mixed with a carrier for betterclinical handling, such as to make a putty or foam implant. A pliableimplant in the form of a putty may be provided by mixing the bioactiveglass with a flowable or viscous carrier. A foam implant may be providedby embedding the bioactive glass in a porous matrix such as collagen(either human or animal derived) or porous polymer matrix. One of theadvantages of a foam implant is that the porous carrier can also act asa site for attaching cells and growth factors, and may lead to a bettermanaged healing.

The carrier material may be porous and may help contribute to healing.For example, the carrier material may have the appropriate porosity tocreate a capillary effect to bring in cells and/or nutrients to theimplantation site. The carrier material may also possess the chemistryto create osmotic or swelling pressure to bring in nutrients to the siteand resorb quickly in the process. For instance, the carrier materialmay be a polyethylene glycol (PEG) which has a high affinity to water.

The bioactive glass may be manufactured by electrospinning, or by laserspinning for uniformity. For example, where the material is desired in afibrous form, laser spinning would produce fibers of uniform diameters.Further, the bioactive glass fibers may be formed having varyingdiameters and/or cross-sectional shapes, and may even be drawn as hollowtubes. Additionally, the fibers may be meshed, woven, intertangled andthe like for provision into a wide variety of shapes.

The bone graft material may be engineered with fibers having varyingresorption rates. The resorption rate of a fiber is determined orcontrolled by its material composition and by its diameter. The materialcomposition may result in a slow reacting vs. faster reacting product.Similarly, smaller diameter fibers can resorb faster than largerdiameter fibers of the same implant. Also, the overall porosity of thematerial can affect resorption rate. Materials possessing a higherporosity mean there is less material for cells to remove. Conversely,materials possessing a lower porosity mean cells have to do more work,and resorption is slower. Accordingly, the bone graft implants maycontain fibers that have the appropriate material composition as well asdiameter for optimal performance. A combination of different fibers maybe included in the implant in order to achieve the desired result.

Equally as important as the material composition and diameter is thepore size distribution of the open porosity and in particular thesurface area of the open porosity. The present bone graft implantsprovide not only an improved pore size distribution over other bonegraft implants, but a higher surface area for the open pores. The largersurface area of the open porosity of the present implants drives fasterresorption by body fluids, allowing the fluid better access to thepores.

Similar to the bioactive glass fibers, the inclusion of bioactive glassgranules can be accomplished using granules having a wide range of sizesor configurations to include roughened surfaces, very large surfaceareas, and the like. For example, granules may be tailored to includeinterior lumens with perforations to permit exposure of the surface ofthe granule's interior. Such granules would be more quickly absorbed,allowing a tailored implant characterized by differential resorbability.The perforated or porous granules could be characterized by uniformdiameters or uniform perforation sizes, for example. The porosityprovided by the granules may be viewed as a secondary range of porosityaccorded the bone graft material or the implant formed from the bonegraft material. By varying the size, transverse diameter, surfacetexture, and configurations of the bioactive glass fibers and granules,if included, the manufacturer has the ability to provide a bioactiveglass bone graft implant with selectively variable characteristics thatcan greatly affect the function of the implant before and after it isimplanted in a patient. The nano and micro sized pores provide superbfluid soak and hold capacity, which enhances the bioactivity andaccordingly the repair process.

Due to the pliability of this fibrous graft material, these samebioactive glass fibers may be formed or shaped into fibrous clusterswith relative ease. These clusters can be achieved with a littlemechanical agitation of the bioactive glass fibrous material. Theresultant fibrous clusters are extremely porous and can easily wick upfluids or other nutrients. Hence, by providing the bioactive glassmaterial in the form of a porous, fibrous cluster, even greater clinicalresults and better handling can be achieved.

The formed and shaped bioactive glass materials of the presentdisclosure, either with or without sintering, share similar attributeswith a finite density material that has been dictated by its processingand the fiber dimensions of the base material (e.g., diameter and lengthof the fibers) that resulted in the cluster formation. The ultra-porousclusters can possess nano, micro, meso, and macro porosity in a gradientthroughout the cluster. Without limitation, a nanopore is intended torepresent a pore having a diameter below about 1 micron and as small as100 nanometers or smaller, a micropore is intended to represent a porehaving a diameter between about 1 to 10 microns, a mesopore is intendedto represent a pore having a diameter between about 10 to 100 microns,and a macropore is intended to represent a pore having a diametergreater than about 100 microns and as large as 1 mm or even larger.Under a consistent manufacturing process, the formed clusters ofbioactive glass can be used with volumetric dosage to fill a bonedefect. Any number of differently sized clusters can be provided forvarious clinical applications.

One of the benefits of providing an ultra-porous bioactive glassmaterial in cluster form is that handling of the material can beimproved. In one manner of handling the cluster of materials, theclusters may be packaged in a syringe with a carrier, and injected intothe bone defect with ease. Another benefit is the additional structuraleffect of having a plurality of clusters of fibers closely packedtogether, forming additional macrostructures to the overall scaffold ofmaterial. Like a sieve, the openings between individual clusters can bebeneficial such as when a filter is desired for various nutrients inblood or bone marrow to concentrate certain desired nutrients at theimplant location.

Of course, it is understood that, while the term cluster is used todescribe the shape of the materials, such term is not intended to limitthe invention to spherical shapes. In fact, the formed cluster shape maycomprise any rounded or irregular shape, so long as it is not a rodshape. In the present disclosure, the term fibrous cluster represents amatrix of randomly oriented fibers of a range of sizes and length.Additional granules or particulates of material may be placed randomlyinside this matrix to provide additional advantages. A variety ofmaterials and structure can optionally be employed to control the rateof resoprtion, osteostimulation, osteogenesis, compression resistance,radiopacity, antimicrobial activity, rate of drug elution, and provideoptimal clinical handling for a particular application.

The use of fused or hardened fiber clusters may be advantageous in someinstances, because the fusing provides relative hardness to theclusters, thereby rendering the hardened clusters mechanically stronger.Their combination with the glass granules further enhances thestructural integrity, mechanical strength, and durability of theimplant. Because larger sized granules or clusters will tend to havelonger resorption time, in previous cases the user had to sacrificestrength for speed. However, it is possible to provide larger sizedgranules or clusters to achieve mechanical strength, withoutsignificantly sacrificing the speed of resorption. To this end,ultra-porous clusters can be utilized as just described for fiber-basedand glass-based clusters. Rather than using solid spheres or clusters,the present disclosure provides ultra-porous clusters that have theintegrity that overall larger sized clusters provide, along with theporosity that allows for speed in resorption. These ultra-porousclusters will tend to absorb more nutrients, resorb quicker, and lead tomuch faster healing and remodeling of the defect.

In some embodiments, the fiber clusters may be partially or fully fusedor hardened to provide hard clusters. Of course, it is contemplated thata combination of both fused fiber clusters (hard clusters) and unfusedor loose fiber clusters (soft clusters) may be used in one applicationsimultaneously. Likewise, combinations of putty, foam, clusters andother formulations of the fibrous graft material may be used in a singleapplication to create an even more sophisticated porosity gradient andultimately offer a better healing response. In some cases, solid porousgranules of the bioactive glass material may also be incorporated intothe implant.

As previously discussed, the ideal bone graft implant must possess acombination of features that act in synergy to allow the bone graftmaterial to support the biological activity of tissue growth andmechanism of action as time progresses. It is known that porosities andpore size distribution play a critical role in the clinical success ofbone graft materials. More specifically, the bone graft implant needs toinclude an appropriate pore size distribution to provide optimized cellattachment, migration, proliferation and differentiation, and to allowflow transport of nutrients and metabolic waste. In addition, in aporous structure the amount and size of the pores, which collectivelyform the pore size gradient, will be directly related to the mechanicalintegrity of the material as well as affect its resorption rate. Havinga stratified porosity gradient will provide a more complex resorptionprofile for the bone graft material, and engineering the material with asuitable pore size gradient will avoid a resorption rate that is toofast or too slow.

As applicants have discovered, this desired pore size distributionincludes a range of porosities that includes macro, meso, micro and nanopores. As previously mentioned, without limitation, a nanopore isintended to represent a pore having a diameter below about 1 micron andas small as 100 nanometers or smaller, a micropore is intended torepresent a pore having a diameter between about 1 to 10 microns, amesopore is intended to represent a pore having a diameter between about10 to 100 microns, and a macropore is intended to represent a porehaving a diameter greater than about 100 microns and as large as 1 mm oreven larger. Accordingly, the bioactive glass material may be providedwith variable degrees of porosity, and is preferably ultraporous. In oneembodiment, the material may have a range of porosities including macro,meso, micro and nano pores. The resultant engineered implant may alsoinclude the same range of porosities, which could be provided as aporous network of matrices within the fibrous scaffold and around thematerial. Accordingly, porosity may be provided inherently by the actualbioactive glass material itself, as well as the matrices separating thematerial within the overall implant.

Another feature of the engineered bone graft implants of the presentdisclosure is their ability to provide mechanical integrity to supportnew tissue growth. Not only should the implant provide the appropriatebiocompatibility and resorption rate, but the surface area should bemaximized to fully support cell proliferation. The engineered implantcan be selectively composed and structured to have differential orstaged resorption capacity, while still being easily molded or shapedinto clinically relevant shapes as needed for different surgical andanatomical applications. Additionally, these engineered implants mayhave differential bioresorbability, compression resistance andradiopacity, and can also maximize the content of active ingredientrelative to carrier materials such as for example collagen.

The present disclosure provides improved bone graft materials and bonegraft implants formed from these materials that are able to sustaintissue growth throughout the healing process. One of the deficiencies ofcurrently available bone graft implants is their lack of ability toprovide proper mechanical scaffolding while supporting cellproliferation over time. The engineered materials and implants of thepresent disclosure overcome this problem by providing, among otherthings, an appropriate combination of porosities (i.e., pore sizedistribution) and high surface area within a porous bioactive glassinfrastructure that serves as an ideal scaffold for tissue growth. Moreimportantly, the range of porosities is distributed throughout theporous bioactive glass infrastructure, which is able to supportcontinued cell proliferation throughout the healing process.

Initially upon implantation, the engineered implants provide a networkof macro, meso, micro and nano pores distributed within a fibrousbioactive glass matrix. These pores can be interconnected, allowing cellmigration throughout the matrix. As surface area is inverselyproportional to the diameter of the pore, the engineered implantsmaximize surface area for cell attachment by providing a desiredsurface-to-volume ratio of nano sized pores. The laws of physics suggestthat these smaller pores are optimal for vascularization. Due to theosmotic pressure of the environment, a capillary effect will be observedwith the nano and micro sized pores that results in biological fluidbeing wicked towards the center of the bioactive glass matrix. Likewise,the larger pores like the macro sized pores are optimal for oxygenationand nutrient exchange within the matrix.

After implantation, a calcium phosphate (CaP) layer forms around theconstruct. This calcium phosphate layer results from the chemicalinteraction of the bioactive glass material and the surroundingbiological environment. At the same time, the smaller sized pores likethe nano sized pores will be resorbing at a rate faster than the rest ofthe implant. As these nano sized pores resorb or become replaced withcells, they will bring in cellular activity and create athree-dimensional biostructure that, within itself, also has its ownporosity. Thus, over time, new cells replace the resorbed material at arate that maintains the mechanical integrity of the new construct. Thenew cells form their own network around the fibrous bioactive glassmatrix, which fibers provide connectivity for the tissue growth. Moreimportantly, because of the widespread distribution of nanoporesthroughout the fibrous matrix, the new cells are present in a densitythat makes the implant mechanically sound.

Unlike traditional bone graft scaffolds, the present bone graft implantsoffer both the necessary structure and function for clinical success,and allow the process of cell proliferation to occur in a non-uniform,multi-faceted fashion with the appropriate balanced rate of new cellproliferation replacing resorbed graft material. More importantly, thisreplacement occurs at select locations within the construct, withoutcompromising overall mechanical integrity. In addition, the materialsand implants allow this new tissue growth process to occur throughoutthe healing process, not just at the beginning of the process. Theconstant and simultaneous activities of cell proliferation andresorption occur throughout the entire healing time with the presentbone graft materials and implants.

In some embodiments, the underlying bioactive material forming thefoundation of the implant may be a bioactive glass. The bioactive glassmay take the form of fibers, making them easy to handle in a clinicalsetting. Accordingly, in one embodiment, the engineered implant may be afibrous scaffold formed of fibrous bioactive glass fibers. These fibersmay be unrestricted, and allowed to move freely over one another.Alternatively, the fibers may be partially or fully fused to provide amore organized, rigid and structured network of fibers. Such a fibrousscaffold would allow for stimulation and induction of the naturalbiologic healing process found in fibrin clots whose mechanism issimilar to that of new bone formation. One theory of the mechanism ofaction as provided by the fibrous nature of the scaffold is providedbelow.

The standard method for healing natural tissue with synthetic materialshas been to provide a device having the microstructure andmacrostructure of the desired end product. Where the desired end productis cancellous bone, traditional bone grafts have been engineered tomimic the architecture of cancellous bone. Although this has been thecurrent standard for bone grafts, it does not take into account the factthat bone is a living tissue. Each bony trabeculae is constantlyundergoing active biologic remodeling in response to load, stress and/ordamage. In addition, cancellous and cortical bone can support a vastnetwork of vasculature. This network not only delivers nutrients tosustain the living environment surrounding bone, but also supports redblood cells and marrow required for basic biologic function. Therefore,merely providing a synthetic material with the same architecture that isnon-biologic is insufficient for optimal bone healing and bone health.Instead, what is required is a mechanism that can recreate the livingstructure of bone.

Traditional synthetics act as a cast, or template, for normal bonetissue to organize and form. Since these synthetics are not naturallyoccurring, eventually the casts or templates have to be resorbed toallow for normal bone to be developed. If these architectured syntheticsdo not resorb and do not allow proper bone healing, they simply becomeforeign bodies that are not only obstacles, but potentially detrimental,to bone healing. This phenomenon has been observed in many studies withslow resorbing or non-resorbing synthetics. Since these synthetics arejust chemically inert, non-biologic structures that only resemble bone,they behave as a mechanical block to normal bone healing anddevelopment.

With the understanding that bone is a living biologic tissue and thatinert structures will only impede bone healing, a different physiologicapproach is presented with the present invention. Healing is a phasicprocess starting with some initial reaction. Each phase builds on thereaction that occurred in the prior phase. Only after a cascade ofphases does the final development of the end product occur—new bonetissue. The traditional method has been to replace or somehow stimulatehealing by placing an inert final product as a catalyst to the healingprocess. This premature act certainly does not account for thephysiologic process of bone development and healing.

The physiologic process of bone healing can be broken down to threephases: (a) inflammation; (b) osteogenesis; and (c) remodeling.Inflammation is the first reaction to injury and a natural catalyst byproviding the chemotactic factors that will initiate the healingprocess. Osteogenesis is the next phase where osteoblasts respond andstart creating osteoid, the basic material of bone. Remodeling is thefinal phase in which osteoclasts and osteocytes then recreate thethree-dimensional architecture of bone.

In a normal tissue repair process, at the initial phase a fibrin clot ismade that provides a fibrous architecture for cells to adhere. This isthe cornerstone of all connective tissue healing. It is this fibrousarchitecture that allows for direct cell attachment and connectivitybetween cells. Ultimately, the goal is to stimulate cell proliferationand osteogenesis in the early healing phase and then allow forphysiologic remodeling to take place. Since the desired end product isliving tissue, the primary objective is to stimulate as much living boneas possible by enhancing the natural fiber network involved ininitiation and osteogenesis as well as angiogenesis.

Fibrous bone graft materials and bone graft implants formed from thesefibrous materials have previously been disclosed in U.S. PatentApplication Publication No. 2011/0144764 entitled “Bone Graft Material”,U.S. Patent Application Publication No. 2011/0144763 entitled “DynamicBioactive Bone Graft Material Having an Engineered Porosity”, and inU.S. Patent Application Publication No. 2011/0316 entitled “DynamicBioactive Bone Graft Material and Methods for Handling”, all of whichare co-pending and co-owned by applicants, the contents of which areincorporated herein by reference. These bone graft implants attempt torecapitulate the normal physiologic healing process by presenting thefibrous structure of the fibrin clot. Since these bioactive implantsmade of fibers are both osteoconductive as well as osteostimulative, thefibrous network will further enhance and accelerate bone induction.Further, the free-flowing nature of the bioactive fibrous matrix orscaffold allows for natural initiation and stimulation of bone formationrather than placing a rigid template that may impede final formation aswith current graft materials. The fibers of the implants can also beengineered to provide a chemical reaction known to selectively stimulateosteoblast proliferation or other cellular phenotypes.

The present disclosure provides several embodiments of fibrous bonegraft implants formed of bioactive glass fibers similar to thosepreviously disclosed by applicants. The bundles of bioactive glassfibers are ultraporous, and include a combination of nano, micro, mesoand macro pores. The fibrous nature of the material allows the bioactiveglass fibers to be easily molded or shaped into clinically relevantshapes as needed for different surgical and anatomical applications,while maintaining the material's porosity. One manner of molding orshaping the scaffold is by placing the fibers into a mold tray, similarto the manner described in U.S. Patent Application Publication No.2011/0316 entitled “Dynamic Bioactive Bone Graft Material and Methodsfor Handling”. The implant may comprise bioactive glass fibers alone, orwith additives as described above.

Another manner of shaping the implant is with the use of a jig. Due tothe fibrous and pliable nature of the base material, it is also possibleto add a biological fluid to the fibrous matrix and press into a formedshape with the fluid contained therein. Of course, it is understood thatthe fibrous material may just as easily be compressed in a mold. Liquidslike bone marrow aspirate, glue or other binding agents may be added tothe material prior to molding. In addition, a solvent exchange may beutilized and the shaped material can be allowed to dry or cure to form ahardened solid scaffold for implantation.

The implants may be provided in clinically relevant shapes. Simpleshapes like cylinders or rods, or a strip, may be convenient for easyimplantation. Alternatively, the implants may take the form of complexshapes to closely match the anatomy of the patient. For example, theimplants may be formed in the shape of a shell, such as for instance anacetabulum shell. In another example, the material may be formed as athin sheet or strip that is capable of being wrapped around the bonearea to be treated, such as a bone defect site, much like a wounddressing. In that instance, the sheet or strip of material would notnecessarily have to be inserted into the wound site, but rather coverthe wound site while still providing the same benefits and acting in thesame manner as the implants described herein.

The implants may be packaged in a clinically useful and friendly tray.The tray may be closed to control density and consequently dosage of theimplant. The dosage may be dictated by the clinical application. It isalso possible to use the tray as a mold, such that the shape of the traycreates a clinically relevant shaped implant. Another benefit of thetray is to allow fluids or liquids to be added to the implant. Suchfluids may include saline, bone marrow, bone marrow concentrate, stemcells, platelet-rich plasma, etc. The closed tray also avoidscontamination of the implant while it is in the operating room beforeimplantation, as it minimizes the need for clinical handling beforeimplantation, and is convenient for transport.

The fibers forming the engineered scaffold have a relatively smalldiameter, and in particular, a diameter in the range of about 500nanometers to about 50 microns, or a diameter in the range of about 0.1to about 100 microns. In one embodiment, the fiber diameter can be lessthan about 10 nanometers, and in another embodiment, the fiber diametercan be about 5 nanometers. In some embodiments, the fiber diameter canbe in the range of about 0.5 to about 30 microns. In other embodiments,the fiber diameter can fall within the range of between about 2 to about10 microns. In still another embodiment, the fiber diameter can fallwithin the range of between about 3 to about 4 microns.

The bioactive glass fibers may be manufactured having predeterminedcross-sectional diameters as desired. In one example, the bone graftimplant may be formed from a randomly oriented matrix of fibers ofuniform diameters. Further, the bioactive glass fibers may be formedhaving varying diameters and/or cross-sectional shapes, and may even bedrawn as hollow tubes. Additionally, the fibers may be meshed, woven,intertangled and the like for provision into a wide variety of shapes.

For example, a bioactive glass fiber implant can be manufactured suchthat each fiber is juxtaposed or out of alignment with the other fiberscould result in a randomly oriented fibrous matrix appearance due to thelarge amount of empty space created by the random relationship of theindividual glass fibers within the implant. Such a manufacture enablesan implant with an overall soft or pliable texture so as to permit thesurgeon to manually form the implant into any desired overall shape tomeet the surgical or anatomical requirements of a specific patient'ssurgical procedure. Such an implant also easily lends itself toincorporating additives randomly dispersed throughout the fibers, suchas those previously described and including bioactive glass granules,antimicrobial fibers, particulate medicines, trace elements or metalssuch as copper, which is a highly angiogenic metal, strontium,magnesium, zinc, etc. mineralogical calcium sources, and the like.Further, the bioactive glass fibers may also be coated with organicacids (such as formic acid, hyaluronic acid, or the like), mineralogicalcalcium sources (such as tricalcium phosphate, hydroxyapatite, calciumcarbonate, calcium hydroxide, calcium sulfate, or the like),antimicrobials, antivirals, vitamins, x-ray opacifiers, or other suchmaterials.

The implant may be engineered with fibers having varying resorptionrates. The resorption rate of a fiber is determined or controlled by,among other things, its material composition and by its diameter. Thematerial composition may result in a slow reacting vs. faster reactingproduct. Similarly, smaller diameter fibers can resorb faster thanlarger diameter fibers. Also, the overall porosity of the material canaffect resorption rate. Materials possessing a higher porosity meanthere is less material for cells to remove. Conversely, materialspossessing a lower porosity mean cells have to do more work, andresorption is slower. Accordingly, the implant may contain fibers thathave the appropriate material composition as well as diameter foroptimal performance. A combination of different fibers may be includedin the implant in order to achieve the desired result. For instance, theimplant may comprise a composite of two or more fibers of a differentmaterial, where the mean diameter of the fibers of each of the materialscould be the same or different.

Equally as important as the material composition and diameter is thepore size distribution of the open porosity and in particular thesurface area of the open porosity. The present bone graft implantsprovide not only an improved pore size distribution over other bonegraft implants, but a higher surface area for the open pores. The largersurface area of the open porosity of the present implants drives fasterresorption by body fluids, allowing the fluid better access to thepores.

Another manner of further enhancing the bioactive graft material of thepresent disclosure is to provide an additional layer or coating ofpolymer over the material in its individual fiber form or in its shapedfibrous cluster form. For example, biocompatible, bioabsorbable polymeror film-forming agents such as polycaprolactones (PCL), polyglycolicacid (PGA), poly-L-Lactic acid (PL-LA), polysulfones, polyolefins,polyvinyl alcohol (PVA), polyalkenoics, polyacrylic acids (PAA), PEG,PLGA, polyesters and the like are suitable materials for coating orbinding the fibrous graft material of the present invention. Theresultant product is strong, carveable, and compressible, and may stillabsorb blood. Other suitable materials also include artificial polymersselected from poly(anhydrides), poly(hydroxy acids), polyesters,poly(orthoesters), polycarbonates, poly(propylene fumerates),poly(caprolactones), polyamides, polyamino acids, polyacetals,polylactides, polyglycolides, polysulfones, poly(dioxanones),polyhydroxybutyrates, polyhydroxyvalyrates, poly(vinyl pyrrolidones),biodegradable polycyanoacrylates, biodegradable polyurethanes,polysaccharides, tyrosine-based polymers, poly(methyl vinyl ether),poly(maleic anhydride), poly(glyconates), polyphosphazines,poly(esteramides), polyketals, poly(orthocarbonates), poly(maleic acid),poly(alkylene oxalates), poly(alkylene succinates), poly(pyrrole),poly(aniline), poly(thiophene), polystyrene, non-biodegradablepolyurethanes, polyureas, poly(ethylene vinyl acetate), polypropylene,polymethacrylate, polyethylene, poly(ethylene oxide), and co-polymers,adducts, and mixtures thereof. The material may be partially or fullywater soluble.

Applying this feature to the fibrous graft material of the presentdisclosure, in one embodiment the individual fibers of the bioactiveglass fiber material may be coated with such a biocompatible polymer.The coating itself would be sufficiently thin so as not to impede theadvantages from the physical attributes and bioactive properties of thebase material as described. In other words, the polymeric coated fiberswould still retain pliability and allow the user to easily mold or formthe fibrous material into the desired shape for implantation. Such apolymeric coating would further enhance the handling of the fibrousmaterial while still allowing the underlying base material to be used inthe same manner as previously described. The polymeric component wouldalso provide a mechanism for graft containment, controlled resorption,and controlled bioactivity or cellular activity. This polymericcomponent may comprise a solid layer, a porous or perforated layer, or amesh or woven layer of material having channels therein for exchange ofnutrients, cells or other factors contained within.

In another embodiment, the fibrous graft material may be formed orshaped into an initial geometry and then coated with the biocompatiblepolymer. For example, the fibrous graft material may be formed intofibrous clusters as previously mentioned. These fibrous clusters canthen be encapsulated in a biocompatible polymer. The resulting implantwould have a fibrous BAG center surrounding which is a polymeric coatingor shell.

In still another embodiment, the fibrous graft material can be formedinto a flat sheet or strip. The biocompatible polymer may be wrappedaround the sheet or strip, encasing the sheet or strip in anenvelope-like fashion. The composite sheet or strip could be cut,folded, rolled, crumpled, or otherwise shaped into a desired geometryappropriate for clinical application.

In yet another embodiment, a combination of fibers and granules orclusters (either fibrous BAG or solid BAG) may be interspersed on asheet of the biocompatible polymer. The fibers or granules may berandomly placed, or layered in an organized pattern on the sheet ofpolymer. For example, a section of the layer could contain fibers only,and an adjacent section could contain granules only. The sheet ofpolymer may then be folded onto itself, rolled into a cylinder, orcrumpled into a ball. Alternatively, the fibers alone or with added BAGgranules (either fibrous BAG or solid BAG) may be shaped into a disc,block, rod, or other uniform shape. The overlapping layers of BAGmaterial and polymer would provide a controlled resorption and cellularactivity profile along the depth of the composite implant. That is, thevariation in location as well as the material of the composite relativeto the implant as a whole allows the user to design an implant with anengineered porosity.

Another variation of this embodiment would encompass a composite implantin which the concentration of material is greater at one end of theimplant than another, such that the controlled resorption and cellularactivity profile along the length of the composite implant. This type ofcomposite implant could be achieved by discretely placing the componentmaterials onto a sheet of polymer, then rolling at an angle so that thematerial is non-uniformly distributed along the length of the rolledconstruct.

The biocompatible polymeric coating may be heat wrapped or heat shrunkaround the underlying fibrous bone graft material. In addition, thebiocompatible polymeric coating may be a mixture of polymer and othercomponents. For example, it is contemplated that the polymeric coatingcan comprise 100% of a particular polymer, such as for instance, PLA.However, a mixture of 50% PLA and 50% PEG may also be utilized.Likewise, the coating may be formed of a polymer—BAG composition. Inthis case, the coating could comprise 50% polymer with the remaining 50%comprising BAG granules or fibers, for instance. Of course, it isunderstood that the percentage of an individual component may vary as sodesired, and the percentages provided herein are merely exemplary forpurposes of conveying the concept.

An alternative material suitable for binding or containing the fibrousgraft material is collagen, which could be provided as a slurry and thenhardened such as by freeze-drying. This collagen could be human-derivedcollagen or animal-derived collagen, for instance.

Additionally, it is contemplated that additional BAG granules, clusters,spheres, etc. or individual fibers may be adhered to the polymericcoating in order to provide a surface enhancement for adherence to theimplant site. These BAG granules or fibers would allow a better frictionfit with the patient, serving as structural features. For example, addedsurface features may include fibers, granules, particulates, and thelike that can be included in the coating to provide an exterior withbioactive anchorage points to attract cellular activity and improveadhesion of the implant in situ.

At the same time, these additional BAG granules or fibers also serve asbioactive features to allow for a differential mechanism of resorptionand a more sophisticated bioactivity profile, since these BAG granulesand fibers are themselves also capable of initiating bioactivity. TheBAG granules or fibers may be used with or without additional coatings,such as with or without the additional polymer coating. Moreover, it isunderstood that part or all of the BAG fibers and materials may besintered or unsintered in these applications.

The addition of the polymeric component to the base fiber graft materialprovides the benefit of allowing ease of handling, but also adds a layerof control to the resorption rate and bioactivity. It could easily becontemplated that the polymeric component in all of the embodimentspreviously described could be porous itself, thereby providing acomposite implant having controlled fluid interactivity. The ability toprovide separate layers of BAG within a single implant also rendersdepth control to the bioactivity, as well as controlled graftcontainment.

The embodiments of the present disclosure are not limited, however, tofibers alone. In other embodiments, the bioactive glass fibers that formthe foundation of the implant may be substituted or supplemented withbioactive granules. These granules may be uniform or non-uniform indiameter, and may comprise a mixture of differently sized diameters ofgranules. In addition, the granules may be formed of the same type ofbioactive glass material, or a mixture of different materials selectedfrom the group of suitable materials previously mentioned. The granulesmay be solid or porous, and in some cases a mixture of both solid andporous granules may be used. Regardless, the engineered implantcomprising the granular foundation should still provide the desired poresize distribution, which includes a range of porosities that includesmacro, meso, micro and nano pores.

Like the fibers, at least some or all of the granules forming theengineered implant may be coated with a polymeric coating. The coatingmay be solid or porous. This coating could be provided on individualgranules, or it could envelope a cluster or group of granules. In otherembodiments, the coating could comprise collagen. For instance, thecoating could be a solid collagen or a perforated collagen. Addedsurface features including fibers, granules, particulates, and the likecan be included in the coating to provide an exterior with bioactiveanchorage points to attract cellular activity and improve adhesion ofthe implant in situ.

In addition, some embodiments may include a mixture of both granularbioactive glass as the primary material with secondary bioactive glassfibers as the carrier material. In such cases, both the primary andsecondary materials are active. The fibrous carrier would be able toresorb quickly to create a chemically rich environment for inducing newcellular activity. Moreover, the fibrous material would serve as selectattachment or anchorage sites for bone forming cells.

In some cases, at least some or all of the fibers or granules formingthe engineered scaffold may be coated with a glass, glass-ceramic, orceramic coating. The coating may be solid or porous. In one embodiment,the coating may be a bioactive glass such as 45S5 or S53P4. In anotherembodiment, the coating may be partially or fully fused. This coatingcould be provided on individual fibers or granules, or it could envelopea cluster or group of fibers or granules. The coating may be partiallyfused or hardened, or fully fused to provide a semi-soft to fullyhardened crust around some or all of the scaffold. A polymer coating orshell may encase the entire construct.

In still further embodiments, the implants may comprise a multi-layeredcomposite of varying or alternating materials. For example, in one casea bioactive glass fiber or granule may be encased in a polymer asdescribed above, and then further encased in a bioactive glass. Thisadditional bioactive glass layer could be the same as, or different,than the underlying bioactive glass. The resultant construct wouldtherefore have varying resorption rates as dictated by the differentlayers of materials.

In addition to providing a structurally sound implant and theappropriate materials and porosities and pore size gradient for cellproliferation, the present bone graft materials and implants may alsoprovide cell signals. This can be accomplished by the incorporation ofbiological agents such as growth factors. These factors may besynthetic, recombinant, or allogenic, and can include, for example, stemcells, deminerealized bone matrix (DBM), as well as other known cellsignaling agents.

In some embodiments, the engineered implants may be also osteoconductiveand/or osteostimulatory. By varying the diameter and chemicalcomposition of the components used in the embodiments, the engineeredimplants may have differential activation (i.e., resorbability), whichmay facilitate advanced functions like drug delivery of such drugs asantibiotics, as an example. One manner of providing osteostimulativeproperties to the implant is to incorporate bone marrow into the fibrousmatrix. The incorporation of the marrow would produce anosteostimulative implant that accelerates cell proliferation.

In other embodiments, the engineered implant may also include traceelements or metals such as copper, zinc, strontium, magnesium, zinc,fluoride, mineralogical calcium sources, and the like. These traceelements provide selective benefits to the engineered structural andfunctioning implants of the present disclosure. For example, theaddition of these trace elements like strontium may increase x-rayopacity, while the addition of copper provides particularly effectiveangiogenic characteristics to the implant. The materials may also becoated with organic acids (such as formic acid, hyaluronic acid, or thelike), mineralogical calcium sources (such as tricalcium phosphate,hydroxyapatite, calcium sulfate, calcium carbonate, calcium hydroxide,or the like), antimicrobials, antivirals, vitamins, x-ray opacifiers, orother such materials. These bone graft materials may also possessantimicrobial properties as well as allow for drug delivery. Forexample, sodium or silver may be added to provide antimicrobialfeatures. In one embodiment, a layer or coating of silver may beprovided around the engineered implant to provide an immediateantimicrobial benefit over an extensive surface area of the implant.Other suitable metals that could be added include gold, platinum,indium, rhodium, and palladium. These metals may be in the form ofnanoparticles that can resorb over time.

Additionally, biological agents may be added to the engineered implant.These biological agents may comprise bone morphogenic protein (BMP), apeptide, a bone growth factor such as platelet derived growth factor(PDGF), vascular endothelial growth factor (VEGF), insulin derivedgrowth factor (IDGF), a keratinocyte derived growth factor (KDGF), or afibroblast derived growth factor (FDGF), stem cells, bone marrow, andplatelet rich plasma (PRP), to name a few. Other medicines may beincorporated into the scaffold as well, such as in granular or fiberform.

In general, the present disclosure provides bone graft materials andimplants formed from these materials that are engineered with acombination of structural and functional features that act in synergy toallow the bone graft implant to support cell proliferation and newtissue growth over time. The implants provide the necessary porosity,pore size distribution and high surface area to allow propervascularization, optimized cell attachment, migration, proliferation,and differentiation. The implants are formed of synthetic materials thatare biocompatible and offer the requisite mechanical integrity tosupport continued cell proliferation throughout the healing process.These implants may comprise a fibrous or granular infrastructure ofporous material encased in polymer.

Embodiments of the present disclosure may be explained and illustratedwith reference to the drawings. It should be understood, however, thatthe drawings are not drawn to scale, and are not intended to representabsolute dimensions or relative size. Rather, the drawings help toillustrate the concepts described herein.

As mentioned, the present disclosure provides an engineered implant thatmay be formed of fibrous bioactive glass material. The implant maycomprise one or more different glass materials to vary the compositionof the implant. In addition, the diameters of each of the materials mayalso vary so as to produce an engineered implant that is selectivelycomposed and structured to have differential or staged resorptioncapacity. In addition, each of the fibers may be individually coatedwith a polymeric coating, such as shown in FIG. 1. The individualbioactive glass fiber 20 may be coated or encased in a polymeric shell30. The coating may be porous, and provide for better handling of thefibrous bioactive glass material.

Rather than coating individual fibers, it is possible to coat the entirefibrous matrix as shown in FIG. 2. The fibrous matrix may comprisefree-flowing, randomly oriented fibers 20 that can be encased in apolymeric coating or shell 30. The shell 30 may be porous, and providefor better handling of the fibrous bioactive glass material. These poresor vents 34 allow free migration of cells and nutrients within theinternal fibrous matrix, thereby improving the healing process. It iscontemplated that in some embodiments, either fibers or granules, or acombination of both, may be added to the coating. The fibers orgranules, which themselves may or may not be coated, would extend beyondthe outer surface of the scaffold, providing a surface feature thatenhances adhesion and creates a cell attachment surface. FIG. 6illustrates this concept.

FIG. 3 represents an exemplary embodiment of an engineered implant 10that may comprise granules 40 in combination with a matrix of fibers 20.In some embodiments, the matrix may comprise fibers 20 of varyingbioactive glass materials. The presence of granular matter may beemployed to modify or control the resorption rate and resorption profileof the implant 10 as well as provide mechanical strength and compressionresistance. The granules may be a bioactive glass, calcium sulfate,calcium phosphate, calcium carbonate, calcium hydroxide, orhydroxyapatite. The granules may be solid, or it may be porous. Thesegranules may serves as anchors for cell attachment, spacers betweenfibers to control distribution and dosage, or carry biological agents toprovide antimicrobial properties or osteostimulative agents.

The inclusion of bioactive glass granules can be accomplished usinggranules having a wide range of sizes or configurations to includeroughened surfaces, very large surface areas, and the like. For example,granules may be tailored to include interior lumens with perforations topermit exposure of the surface of the granule's interior. Such granuleswould be more quickly absorbed, allowing a tailored materialcharacterized by differential resorbability. The perforated or porousgranules could be characterized by uniform diameters or uniformperforation sizes, for example. The porosity provided by the granulesmay be viewed as a secondary range of porosity accorded the bone graftmaterial or the implant formed from the bone graft material. By varyingthe size, transverse diameter, surface texture, and configurations ofthe bioactive glass fibers and granules, if included, the manufacturerhas the ability to provide a bioactive glass bone graft material withselectively variable characteristics that can greatly affect thefunction of the material before and after it is implanted in a patient.The nano and micro sized pores provide superb fluid soak and holdcapacity, which enhances the bioactivity and accordingly the repairprocess.

Accordingly, the engineered implant can be selectively determined bycontrolling compositional and manufacturing variables, such as bioactiveglass fiber diameter, size, shape, and surface characteristics as wellas the amount of bioactive glass granule content and structuralcharacteristics, and the inclusion of additional additives, such as, forexample tricalcium phosphate, hydroxyapatite, and the like. Byselectively controlling such manufacturing variables, it is possible toprovide an artificial bone graft material having selectable degrees ofcharacteristics such as porosity, bioabsorbability, tissue and/or cellpenetration, calcium bioavailability, flexibility, strength,compressibility and the like.

FIGS. 4A-4C represent exemplary embodiments of fibers contained withinpolymer. FIG. 4A represents an exemplary embodiment of an engineeredimplant 110 that may comprise fibers 20 formed into a fibrous cluster.The bioactive glass fibers may be formed into these clusters, withrelative ease. These clusters can be achieved with a little mechanicalagitation of the bioactive glass fibrous material. The resultant fibrousclusters are extremely porous and can easily wick up fluids or othernutrients. Hence, by providing the bioactive glass material in the formof a porous, fibrous cluster, even greater clinical results and betterhandling can be achieved. The materials of the fibers 20 may be thesame, or of varying bioactive glass materials. As shown in FIG. 4A, thefiber cluster may further include a polymeric coating 30.

Optionally, short fibrous material may extend from the outside of theclusters to create anchorage sites. The individual fibers may be coatedwith a polymeric coating, similar to the one already described.Alternatively, the entire fibrous ball may be coated with the polymer,which may also be porous.

In addition, these fibrous clusters 120 may be hardened by heating themat elevated temperatures, such as shown in FIG. 4B. The fused fibrousclusters 120 no longer have freely moving fibers 20, since certainfibers may attach at fused intersections 22. The cluster 120 may includea polymeric coating or shell 30. In addition, the cluster 120 mayoptionally include hardened fibers on the exterior surface, which act asspikes 146 around the clusters 120.

In some cases, the sintered fibrous clusters 130 may or may not presentfibrous architecture, as shown in FIG. 4C. In this example, the porousclusters 130 have fused such that the original fibrous architecture isundetected. Instead, the cluster 130 appears to be a porous bioactiveglass granule 26 with pores or voids 28.

As mentioned, the presence of granular matter may be employed to modifyor control the resorption rate and resorption profile of the fiberclusters. FIG. 5 shows an embodiment of an engineered implant 140comprising fibers 20 and granules 40 similar to those previouslydescribed. The granules may be solid, porous, or sintered, and mayfurther be coated with a polymeric coating 30. As with previousembodiments, the implant may include exterior surface features such assoft, wavy short fibers or hardened fiber spikes.

The formed and shaped bioactive glass materials of the presentdisclosure, either with or without sintering, share the similarattributes of a finite density material that has been dictated by itsprocessing and the fiber dimensions of the base material (e.g., diameterand length of the fibers) that resulted in the cluster formation. Theultra-porous clusters can possess micro, meso, and macro porosity in agradient throughout the ball. Under a consistent manufacturing process,the formed clusters of bioactive glass can be used with volumetricdosage to fill a bone defect. Any number of differently sized clusterscan be provided for various clinical applications.

It is contemplated that in some embodiments where a polymeric coating isapplied, either fibers or granules, or a combination of both, may beadded to the coating. The fibers or granules, which themselves may ormay not be coated, would extend beyond the outer surface of the implant,providing a surface feature 42 that enhances adhesion and creates a cellattachment surface. As shown in FIG. 6, the shell 30 may also includeshort wavy fiber segments 42 that serve as surface features to enhanceanchorage of the implant 150 in situ. These short wavy fiber segments 42may be the fibers 20 extending out of the shell 30, or it may bediscrete short fiber segments 42 added to the shell 30.

FIG. 7 represents an exemplary embodiment of an engineered implant 200comprising two fibrous clusters 20A, 20B, one within the other, suchthat the cross-sectional view appears as two layers of fibers envelopedby polymer 30. As with the previously described clusters, the clusters20A, 20B may be solid, porous, or sintered, and may further be coatedwith a polymeric coating 30. The material of the fibrous clusters 20A,20B may be the same or different. The implant may optionally comprisegranules, fibers or other additives as previously mentioned.

In addition, it is also possible to provide a construct representing acomposite of bioactive glass materials not only in different shapes(i.e., fibers versus granules) but also different formulations. Forexample, in one embodiment, a bioactive glass material is provided as adissolved concentrated solution that may be incorporated into the fibersor granules of the primary bioactive glass component of the implant. Inone case, a borate-based bioactive glass may be dissolved, andintroduced into the pores of a silica-based borate bioactive glassmaterial. The dissolved borate-based material acts as a medicinal agent,releasing a burst of dissolution product upon implantation withouthaving to wait for the underlying, primary silica-based bioactive glassmaterial to dissolve. That is, the dissolved bioactive glass material iscarried within the porous matrix formed by the primary bioactive glassmaterial and delivered via this porous matrix. This provides the userwith the benefits of a second bioactive glass component without havingto alter the implant of the carrier, or primary bioactive glassmaterial. In addition, such an example would allow the use of morechemically stable glasses without the loss of the benefit of fasterreacting or resorbing glasses. The dissolution product also serves tohelp upregulate biologically active agents such as BMP, for instance.

One of the benefits of providing an ultra-porous bioactive glassmaterial in cluster or granular form is that handling of the materialcan be improved. In one manner of handling the granular material, thegranules may be packaged in a syringe with a carrier, and injected intothe bone defect with ease. Another benefit is the additional structuraleffect of having a plurality of clusters closely packed together,forming additional macrostructures to the overall scaffold of material.Like a sieve, the openings between individual clusters can be beneficialsuch as when a filter is desired for various nutrients in blood or bonemarrow to concentrate certain desired nutrients at the implant location.

While granular matter may be employed to modify or control theresorption rate and resorption profile of the fiber clusters, it islikewise also possible to provide an engineered implant having nofibers. FIG. 8 shows an implant 220 comprising fibrous clusters 40encased in polymer 30. Of course, it is understood that the clustersthemselves may also be encased in glass, glass-ceramic, or ceramic. Insome embodiments, the clusters may be replaced with, or supplementedwith, granules that may reside within the fibrous clusters 40. Thegranules (not shown) may be solid, porous, or sintered, and may furtherbe coated with a glass, glass-ceramic, or ceramic coating. The clusters40 provide the base for bone-forming cells, and in this example, thecluster-based matrix may serve as the carrier material for the granules.As FIG. 9 shows, the implant may optionally comprise fibers 20 or otheradditives as previously mentioned. These fibers 20 may be of the same,or different material, than the clusters, and be additionally coated asdescribed above.

Another implant useful for clinical applications is a kneadable,conformable, or otherwise moldable formulation or putty. Putty implantsare desirable because the putty can be applied directly to the injurysite by either injection or by plastering. Putty implants are also easyto handle and moldable, allowing the clinician the flexibility to formthe material easily and quickly into any desired shape. In addition, theputty possesses the attributes of malleability, smearability, andinjectability.

Accordingly, the bioactive glass material may be mixed with a carriermaterial for better clinical handling, such as to make a putty or foamimplant. A pliable implant in the form of a putty may be provided bymixing the bioactive glass material with a flowable or viscous carrier.A foam implant may be provided by embedding the bioactive glass materialin a porous matrix such as collagen (either human or animal derived) orporous polymer matrix. One of the advantages of a foam implant is thatthe porous carrier can also act as a site for attaching cells and growthfactors, and may lead to a better managed healing.

The carrier material may be porous and may help contribute to healing.For example, the carrier material may have the appropriate porosity tocreate a capillary effect to bring in cells and/or nutrients to theimplantation site, similar to the benefits that the fibers provide. Thecarrier material may also possess the chemistry to create osmotic orswelling pressure to bring in nutrients to the site and resorb quicklyin the process. For instance, the carrier material may be a polyethyleneglycol (PEG) which has a high affinity to water.

In one embodiment, the putty may have a more viscous than kneadableconsistency to allow to be easily injected from a syringe or otherinjection system. This could be very useful in a minimally invasivesystem where you want as little disruption to the damaged site and tothe patient as possible. For instance, a treatment may involve simplyinjecting the flowable putty of material into the area of bone damageusing a syringe, cannula, injection needle, delivery screw, or othermedical delivery portal for dispersal of injectable materials. Thistreatment may be surgical or non-surgical.

The combination of the ultra-porous fibrous clusters formed of bioactiveglass, combined with porous bioactive glass granules and a carriermaterial, forms an improved putty implant over currently availableputties. In one embodiment, the putty may comprise fibers and fiberclusters in a carrier material. In another embodiment, the putty maycomprise fibrous clusters as previously mentioned, bioactive glassgranules, and the carrier material, the fibers and granules beingpolymerically coated as described above. The sintered fibrous clustersas well as the bioactive glass granules may be porous, where eachcomponent may have a range or gradient of porosities throughout. Thecombination thus provides the putty with variable resorption rates. Asmentioned above, these fiber and glass clusters may be engineered withvariable porosities, allowing the customization of the puttyformulation. In some embodiments, the putty includes any combination ofnanopores, macropores, mesopores, and micropores.

The carrier material for the putty implant can be phospholipids,carboxylmethylcellulose (CMC), glycerin, polyethylene glycol (PEG),polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), or othercopolymers of the same family. Other suitable materials may includehyaluronic acid, or sodium alginate, for instance. The carrier materialmay be either water-based or non-water based, and may be viscous.Another carrier material alternative is saline or bone marrow aspirate,to provide a stickiness to the implant. Additives such as thosedescribed above, such as for example, silver or another antimicrobialcomponent, may also be added to provide additional biologicalenhancements.

In other embodiments, the collagen may be a fully or partially watersoluble form of collagen to allow the collagen to soften with theaddition of fluids. In still other embodiments, the collagen may acombination of soluble and fibrous collagen. The collagen may be humanderived collagen, in some instances, or animal derived collagen.

The use of sintered fiber clusters may be advantageous in someinstances, because the sintering provides relative hardness to theclusters, thereby rendering the sintered clusters mechanical stronger.Their combination with the glass granules further enhances thestructural integrity, mechanical strength, and durability of theimplant. Because larger sized granules or clusters will tend to havelonger resorption time, in previous cases the user had to sacrificestrength for speed. However, as applicants have discovered, it ispossible to provide larger sized granules or clusters to achievemechanical strength, without sacrificing the speed of resorption. Tothis end, ultra-porous clusters may be utilized. Rather than using solidspheres or clusters, ultra-porous clusters that have the integrity thatoverall larger sized clusters provide, along with the porosity thatallows for speed in resorption, can be used. These ultra-porous clusterswill tend to absorb more nutrients, resorb quicker, and lead to muchfaster healing and remodeling of the defect.

It is contemplated that the putty could be formulated for injectabledelivery. For example, one manner in which to apply the putty wouldinclude a syringe containing the bioactive material that can be openedto suction into the syringe the necessary fluid to form the putty, whilethe same syringe can also be used to inject the as-formed putty implant.In other examples, a syringe with threaded attachments such as aremovable cap may be utilized for site-specific delivery.

In some embodiments, an engineered implant comprising fibers formed intoa cluster in the manner previously described, along with unsinteredfibers of a different material may be provided. The unsintered fiberswould serve as the carrier for the fibrous clusters. A putty implantcould be formed by adding saline or blood marrow aspirate, to provide astickiness to the implant. Thus the putty could include two differentbioactive glass materials.

In still another embodiment, the graft material may be provided in theform of a foam. For example, the addition of collagen to the base graftmaterial would produce a foam implant that could be shaped into strips,sheets, or cylindrical rolls. These strips, sheets, or rolls could thenbe easily cut, folded, or otherwise formed into the ultimate geometry ofthe implant. In addition, these sheets may serve as a wound dressing orwrap around the bone defect site for healing.

As previously mentioned, the fiber clusters may be sintered to providehard clusters. Of course, it is contemplated that a combination of bothsintered fiber clusters (hard granules) and unsintered clusters (softgranules) may be used in one application simultaneously. Likewise thecombination of putty, foam, and clusters as described herein may be usedin a single application to create an even more sophisticated porositygradient and ultimately offer a better healing response. In some cases,solid porous clusters of the bioactive glass material may also beincorporated into the composition.

Additionally, these fibrous clusters may be encased or coated with apolymer. The coating material itself may be porous. Thus, a fibrouscluster may be further protected with a coating formed of polymer. Theadvantage of coating these fibrous clusters is to provide betterhandling since highly porous materials tend to have low strength, areprone to breakage and can become entangled. The addition of a coatinghaving the same properties as the underlying fibrous foundation wouldtherefore create a cluster-like composition that offer yet another layerof protection as well as an additional porosity gradient.

It is contemplated that various compositions and formulations of theinvention of the present disclosure can be achieved through combinationsof the major components of the bioactive glass implant and polymericcontainment layer as described. For example, one combination can includea single material of either fibrous or granular bioactive material laidonto a polymeric base layer, which can then be rolled into a cylindricalshape and delivered to an implantation site. Alternatively, after beingrolled, the implant may be shaped or cut as desired and then insertedinto the site. If so desired, the roll may be sealed.

FIG. 10A shows a sheet of polymer 30 having vents 34 onto which is laida matrix of fibers 20 of the present disclosure. As the sheet 30 isrolled up, a composite layered implant 300 is created, as illustrated inFIG. 10B. The implant 300 may have uniformly distributed fibers 20throughout the layers (i.e, along the depth) and along the length of therolled implant 300.

Of course, it is contemplated that a composite bone graft implant havevariable concentration of material can be created. For instance, asshown in FIG. 11A, the layer of polymer may include discretely laidquantities of different materials. In the present example, fibers 20 maybe laid at one end of the sheet of polymer 30, while fibrous clusters 40may be laid at another end. Upon rolling the sheet 30 together, alayered composite implant 320 is created whereby the fibrous clusters 40reside nearer the center of the roll, while the fibers 20 reside closerto the exterior of the roll, as seen in FIG. 11B. Optionally, thepolymeric sheet 30 may further include pores or vents 34 to allowexchange of fluids and nutrients, for instance.

The same configuration shown in FIG. 11A would also produce a differentresultant construct if the sheet of polymer was rolled at an angle. Thefinal product would produce a composite implant in which the materialswere concentrated at different ends of the rolled implant. Accordingly,numerous configurations are contemplated for the implants to createcomplex resorption profiles.

FIG. 12 represents an exemplary embodiment of one combination in which aplurality of materials comprising fibers 20 and granules or clusters 40of bioactive glass material are laid onto a polymeric base layer 30,which can then be rolled into a cylindrical shape and delivered to animplantation site. Alternatively, after being rolled, the implant may beshaped or cut as desired and then inserted into the site. If so desired,the roll may be sealed as shown in FIG. 12 to form the implant 340.Additional other agents or components may also be added, such as thosepreviously described like the antimicrobial agents.

As mentioned, the materials may be discretely laid in a prearrangedorder so that a material may be concentrated on the interior of theroll, while a different material may be concentrated near the exteriorof the roll. In other words, the materials may be selectivelyconcentrated in discrete pockets depending on the arrangement of thematerial on the polymeric base layer. This type of discrete arrangementof the materials results in a layering effect of the graft materials.FIG. 12 illustrates an embodiment of a composite implant 340 in whichthe plurality of materials are uniformly scattered over the polymericbase component, creating a roll that has substantially evenlydistributed materials throughout the depth of the roll.

Of course, it is understood that multiple layers of materials may beapplied, either as discrete layers or as a mixture, depending on thenumber of layers desired. In addition, a composite of multiple layers ofthe polymeric base with layers of the material, either in discretesections on a single layer or as an entire layer itself, can beenvisioned whereby the materials create a stacking effect to form ablock of bone graft material.

As shown in the scanning electron micrographs of FIGS. 13 to 16, thefibrous matrix of the implant may take the form of a cluster, such asshown in FIG. 13, whereby the fibrous architecture of the implant isevident. This fibrous architecture provides the implant with a structurethat mimics the structure of a human fibrin clot. Granules may beincorporated into the fibrous matrix, and such granules may extend outof the exterior of the implant, as shown in FIG. 14.

FIG. 15 shows a fibrous granule having a partially hardened shell. Thisshell is also porous to allow cell and nutrient exchange. As shown ingreater detail in FIG. 16, individual fibers within the fibrous matrixof the granule are also porous.

In some embodiments, the fiber diameter may be in the range of about 0.1to about 100 microns. In other embodiments, the diameter can be therange of about 0.5 to about 30 microns. In still other embodiments, thediameter can be less than about 10 microns. In one embodiment, the fiberdiameter can fall within the range of between about 2 to about 10microns.

In some embodiments, the fiber clusters may have a diameter in the rangeof about 0.75 to about 4.0 mm. In other embodiments, the fiber clustersmay have a diameter in the range of about 2.0 to 4.0 mm.

In some embodiments, the glass granules may have a diameter in the rangeof about 1 to 5 mm, or about 950 microns to about 3 mm, or about 850microns to about 3 mm. In other embodiments, the glass granules may havea diameter in the range of about 50 to 450 microns, or about 150 to 450microns.

The following are examples of methods to package and deliver bioactiveglass fibers, porous clusters, or other biologic components by means ofone or more polymeric coatings, polymer composite coatings, orpolymer/polymer composite containers.

EXAMPLE 1

Example 1 provides a container or bag that contains a single biologiccomponent, such as M45 porous bioactive clusters. The bag may be madefrom a PCL sheet that was cast by a thin film casting method. The PCLsheet may be folded in half and sealed on two sides (thermal treatment)leaving one side open to insert the M45. Once the M45 is put in the bag,the final edge can sealed. This form of the current embodiment allowsthe clinician to more easily handle and place the biologic (M45) in abone defect site by containing the clusters without adding a carrier.Other versions of this design could include: (a) multiple biologicmaterials (multiple glasses/ceramics/fibers/frit/implants/porousclusters); (b) bone marrow aspirate or human bone; (c) a porous bagwhich will allow blood or other liquids (Infuse/drugs in general) tointeract with the clusters prior to implantation; (d) addition ofbioactive glass or other biologic to the PCL to increase itsbioactivity; (e) addition of a silver/metallic ion releasing agent toPCL or biologic kill bacteria; and (f) a paper example would be to stackmultiple bags together and seal them to form a layered composite.

EXAMPLE 2

Example 2 provides M45 porous clusters coated by a PCL sheet that isrolled up and finally coated with an outer layer of PCL to improvehandling. This implant will again contain the clusters and allow foreasy placement without adding a putty component. The rolled sheet willallow for tissue penetration earlier as there is no putty to dissolveand the sheet will hold the clusters in place as long as the sheet hasnot dissolved, which should prolong the occurrence of any settling thatmight take place in the defect site.

EXAMPLE 3

Example 3 is similar to Example 2, except a bag is used to contain theclusters which makes the implant a little easier to make. In thisexample the clusters are not bonded to the sheet, but they are wrappedmultiple times. Different embodiments could have the biologic bonded tothe sheet first, but in general, the biologic is evenly dispersed in abag and then rolled up and sealed to make a cylindrical dowel typeimplant.

EXAMPLE 4

Example 4 is an extension of Example 3 where a bag is used to containmultiple biologic materials. In Example 4, the first implant material isF45, it is sealed, then a second material comprising M45 porous clustersis added and sealed, and last a third layer containing borate glass fritwhich contains copper (for angiogenic stimulation) is added and sealed.The bag is rolled up and sealed, and the rolling effectively formslayers of implant material from the outside to the center. This can beused to elicit different biological responses or significantly vary theporosity and microstructure of the overall implant.

Although the engineered implant of the present disclosure is describedfor use in bone grafting, it is contemplated that the implant of thepresent disclosure may also be applied to soft tissue or cartilagerepair as well. Accordingly, the application of the implant providedherein may include many different medical uses, and especially where newconnective tissue formation is desired. One such clinical application isin the area of nucleus replacement, where the engineered implant couldbe inserted into the disc nucleus as part of a nucleus replacementtherapy. Another suitable clinical application is for large bone defectsor lesions, particularly with the addition of platelet rich plasma (PRP)to the implant composition. Even still, the implant may be applied as abone filler such as a replacement or substitute for bone cement in bonedefect repairs. A silane coating may be applied over the implant to makeit more suitable in that capacity.

Other embodiments of the invention will be apparent to those skilled inthe art from consideration of the specification and practice of thedisclosure provided herein. It is intended that the specification andexamples be considered as exemplary only, with a true scope and spiritof the disclosure being indicated by the following claims.

What is claimed is:
 1. A porous, composite bone graft implantcomprising: a first component comprising a bioactive glass; and a secondcomponent comprising a polymeric material; each of the components havinga different resorption capacity than the other component; wherein thecomposite implant comprises a pore size distribution including porescharacterized by pore diameters ranging from about 100 nanometer toabout 1 millimeter.
 2. The implant of claim 1, wherein the bioactiveglass is selected from the group consisting of sol gel derived bioactiveglass, melt derived bioactive glass, silica based bioactive glass,silica free bioactive glass, crystallized bioactive glass, and bioactiveglass containing trace elements.
 3. The implant of claim 2, wherein thebioactive glass comprises a silica free bioactive glass selected fromthe group consisting of borate based bioactive glass and phosphate basedbioactive glass.
 4. The implant of claim 2, wherein the bioactive glasscomprises a partially crystallized or fully crystallized bioactiveglass.
 5. The implant of claim 2, wherein the bioactive glass comprisesS70C30, 45S5, S53P4, 58S, or 13-93 glass.
 6. The implant of claim 1,wherein the first component comprises bioactive glass fibers orbioactive glass granules.
 7. The implant of claim 1, wherein the firstcomponent is partially or fully sintered.
 8. The implant of claim 1,wherein the second component comprises a bioabsorbable polymer.
 9. Theimplant of claim 1, wherein the second component is a porous coating.10. The implant of claim 1, wherein the second component comprises acombination of two or more polymers.
 11. The implant of claim 1, whereinat least one of the components is porous.
 12. The implant of claim 6,wherein the first component comprises bioactive glass fibers, and thesecond component comprises a coating over each of the fibers.
 13. Theimplant of claim 6, wherein the first component comprises bioactiveglass fibers, and the second component comprises a coating over theplurality of fibers.
 14. The implant of claim 6, wherein the firstcomponent comprises bioactive glass fibers, and the second componentcomprises a woven layer surrounding the plurality of fibers.
 15. Theimplant of claim 6, wherein the first component comprises bioactiveglass granules, and the second component comprises a coating over eachof the granules.
 16. The implant of claim 6, wherein the first componentcomprises bioactive glass granules, and the second component comprises acoating over the plurality of granules.
 17. The implant of claim 6,wherein the first component comprises bioactive glass granules, and thesecond component comprises a woven layer surrounding the plurality ofgranules.
 18. The implant of claim 1, further including surface featureson the implant to enhance anchorage of the implant.
 19. The implant ofclaim 18, wherein the surface features comprise fibers, granules,spikes, or surface roughenings.
 20. The implant of claim 1, furtherincluding a third component comprising a bioactive material in the formof granules.
 21. The implant of claim 20, wherein the granules areporous.
 22. The implant of claim 20, wherein the granules may comprisebioactive glass, calcium sulfate, calcium phosphate, calcium carbonate,calcium hydroxide, or hydroxyapatite.
 22. The implant of claim 20,wherein the granules are contained in a coating and are configured toserve as surface enhancements to anchor the implant.
 24. The implant ofclaim 20, wherein the granules may be partially or fully sintered. 25.The implant of claim 1, further comprising an additive selected from thegroup consisting of medicine, trace element or metal, organic acid,mineralogical calcium source, antimicrobial, antiviral, vitamin, andx-ray opacifier.
 26. The implant of claim 25, wherein the trace elementcomprises copper, strontium, magnesium, or zinc.
 27. The implant ofclaim 25, wherein the organic acid comprises formic acid or hyaluronicacid.
 28. The implant of claim 25, wherein the mineralogical calciumsource comprises tricalcium phosphate, hydroxyapatite, calciumcarbonate, calcium hydroxide, or calcium sulfate.
 29. The implant ofclaim 25, wherein the antimicrobial comprises sodium or silver.
 30. Theimplant of claim 25, wherein the additive is in the form of a fiber orgranule.
 31. The implant of claim 1, further comprising a biologicalagent.
 32. The implant of claim 31, wherein the biological agentcomprises a bone morphogenic protein, a peptide, a bone growth factor, aplatelet derived growth factor, a vascular endothelial growth factor, aninsulin derived growth factor, a keratinocyte derived growth factor, afibroblast derived growth factor, a stem cell, bone marrow, or plateletrich plasma.
 33. The implant of claim 1, further comprising a pluralityof layers, wherein the volumetric ratio of first component to secondcomponent within each layer is the same throughout the implant.
 34. Theimplant of claim 1, further comprising a plurality of layers, whereinthe volumetric ratio of first component to second component within onelayer is different than an adjacent layer within the implant.
 35. Theimplant of claim 1, wherein the first component is uniformly distributedthroughout the implant.
 36. The implant of claim 1, wherein the firstcomponent is non-uniformly distributed throughout the implant.
 37. Theimplant of claim 20, further comprising a plurality of layers, whereinthe volumetric ratio of first and second components to the thirdcomponent within each layer is the same throughout the implant.
 38. Theimplant of claim 20, further comprising a plurality of layers, whereinthe volumetric ratio of first and second components to the thirdcomponent within one layer is different than an adjacent layer withinthe implant.
 39. The implant of claim 20, wherein the third component isuniformly distributed throughout the implant.
 40. The implant of claim20, wherein the third component is non-uniformly distributed throughoutthe implant.